RATIONALE: Quality-of-life assessment of patients undergoing cancer treatment may help determine the intermediate- and long-term effects of treatment in patients with cancer. PURPOSE: Clinical trial to determine the quality of life of patients who have previously treated ovarian cancer.

Condition	Treatment or Intervention
recurrent ovarian germ cell tumor stage II ovarian germ cell tumor stage III ovarian germ cell tumor stage IV ovarian germ cell tumor stage I ovarian germ cell tumor Quality of Life	Procedure: supportive care  Behavior: supportive care/therapy  Behavior: psychosocial assessment/care  Procedure: quality-of-life assessment

Further Study Details: 

OBJECTIVES: I. Compare quality of life in terms of health status, sexual functioning, psychological/emotional well being, and social functioning in ovarian germ cell cancer survivors vs a matched healthy control group. II. Predict quality of life in these patients through the additive effects of cancer diagnosis and treatment, sociodemographic characteristics, other stressors, and social network variables.

PROTOCOL OUTLINE: Patients identify up to 3 healthy acquaintance controls within 3 years of the same age. Patients and controls complete a written questionnaire, which takes about 30 minutes, and a telephone interview, which takes about 1 hour, to assess quality of life.

PROJECTED ACCRUAL: A total of 190 patients and 190 healthy controls will be accrued for this study within 2 years.

Ages Eligible for Study:  18 Years and above

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

• History of early or advanced ovarian germ cell tumors
• Continuously disease free for at least 2 years prior to study
• Must have been enrolled on GOG protocols 45, 78, 90, and 116 or similar protocols of cisplatin-based chemotherapy at M.D. Anderson Cancer Center

--Prior/Concurrent Therapy--

• Biologic therapy: Not specified
• Chemotherapy: See Disease Characteristics
• Endocrine therapy: Not specified
• Radiotherapy: No prior radiotherapy
• Surgery: Not specified

--Patient Characteristics--

• Age: 18 and over
• Performance status: Not specified
• Life expectancy: Not specified
• Hematopoietic: Not specified
• Hepatic: Not specified
• Renal: Not specified
• Other: Must be able to complete a written questionnaire and telephone interview in English

California
      Chao Family Comprehensive Cancer Center, Orange,  California,  92868,  United States
Illinois
      Evanston Northwestern Health Care, Evanston,  Illinois,  60201,  United States
Indiana
      Indiana University Cancer Center, Indianapolis,  Indiana,  46202-5289,  United States
Texas
      University of Texas - MD Anderson Cancer Center, Houston,  Texas,  77030-4009,  United States

Study chairs or principal investigators

Stephen D. Williams,  Study Chair,  Gynecologic Oncology Group   

Study ID Numbers:  CDR0000066937; GOG-9901
Record last reviewed:  October 2003
Last Updated:  October 13, 2004
Record first received:  November 1, 1999
ClinicalTrials.gov Identifier:  NCT00003794
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08